Acute Phase Reactant in Non-COVID-19 Bacterial Pneumonia

• Sponsor: Cairo University (Other)
• Overall Status: Completed
• CT.gov ID: NCT05926089
• Collaborator: (none)
• Enrollment: 51
• Location: 1
• Actual Duration (Months): 7.9
• Patients Per Site Per Month: 6.4

Study Details

Study Description

Brief Summary

This study is a cross-sectional study, was conducted at Chest department of Kasr Al-ainy Hospital, Cairo university during the period between October 2020 and April 2021.

The aim of the work was to evaluate levels of acute phase reactants(APR) in Non-COVID-19 bacterial pneumonia, and to correlate between levels of APR and the disease severity.

Condition or Disease	Intervention/Treatment	Phase
Pneumonia; Acute-Phase Reaction	Diagnostic Test: Blood sampling

Detailed Description

51 patients were included in our study, diagnosed as Non-COVID pneumonia

Inclusion criteria:

1. PCR(polymerase chain reaction) negative for COVID.

2. All patients of both sexes with pneumonia .

Exclusion criteria:

1. Non pulmonary infections.

2. Post surgery patients.

3. Renal patients.

4. hepatic patients.

5. Cardiac patients.

6. Recent pulmonary embolism.

Methodology in details:

All patients were subjected to:

1. Full history with emphasis on:

• Epidemiological features (age, gender).

• Risk factors (smoking, DM).

• Clinical presentation (cough, Fever and duration of illness).

1. Clinical examination (local chest examination).

2. Laboratory investigations: venous blood samples were taken to measure APR

Study Design

• Study Type: Observational
• Actual Enrollment: 51 participants
• Observational Model: Case-Only
• Time Perspective: Cross-Sectional
• Official Title: Acute Phase Reactant in Non-COVID-19 Bacterial Pneumonia
• Actual Study Start Date: Oct 1, 2020
• Actual Primary Completion Date: Apr 30, 2021
• Actual Study Completion Date: May 30, 2021

Outcome Measures

Primary Outcome Measures

1. measurement of APR levels in non-Covid-19 pneumonia [6 months]

   assessment of the level of APR and its relation to disease severity

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• COVID-19 negative bacterial pneumonia

Exclusion Criteria:

• COVID-19 positive

• other non-pulmonary infections

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Kasr alainy school of medicine	Cairo		Egypt	11562

Sponsors and Collaborators

• Cairo University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Eman Kamal Ibrahim Hassan, Assistant Professor of pulmonology, Cairo University
• ClinicalTrials.gov Identifier: NCT05926089
• Other Study ID Numbers: MS-358-2020
• First Posted: Jul 3, 2023
• Last Update Posted: Jul 3, 2023
• Last Verified: Jun 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Pneumonia; Pneumonia, Bacterial; Acute-Phase Reaction

Study Results

No Results Posted as of Jul 3, 2023